Flexible and frozen sugar-modified nucleic acids--modulation of biological activity through furanose ring dynamics in the antisense strand.
A comparison of carbohydrate modified nucleic acids has identified key structural characteristics in antisense oligonucleotides (AON) that are necessary for sufficient clinical utility, including increased duplex stability towards RNA complements and improved hydrolytic resistance towards general serum and cellular nucleases. As such, the exogenous addition of short, synthetic oligonucleotides can influence cellular RNA metabolism at any or all levels of replication, transcription or translation by tight and specific hybridization with a chosen target and subsequently stop further function at that site. Furthermore, appropriate modification of the sugar residue may prove to be a vital design element in future AONs that operate by promoting enzyme assisted catalytic destruction of the mRNA target. Unfortunately, many of the current AON designs have provided little insight on the particular structural role of the AON towards enzymatic discrimination of the resultant hybrid. The use of RNase H as a cellular vehicle to assist the inhibitory potency of an AON as well as possible ways of enhancing activity in pre-existing antisense candidates are presented. Of the emerging criteria in this aspect, a balance between flexibility and rigidity within the AON appears to be a critical mediator of the RNase H assisted antisense effect. Accordingly, this review describes the conformational features and selected biological attributes of some of the more prominent AON contenders with a focus on the conformational criteria by which ribonuclease H activity is recruited to a particular hybrid target.
Mangos
Maria M
MM
Department of Chemistry, McGill University, 801 Sherbrooke St. West, Montreal, QC H3A 2K6, Canada. masad.damha@mcgill.ca
Damha
Masad J
MJ
D006801:Humans; D009690:Nucleic Acid Conformation; D016376:Oligonucleotides, Antisense / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D010429:Pentoses / Q000737:chemistry*; D012333:RNA, Messenger / Q000037:antagonists & inhibitors; D016914:Ribonuclease H / Q000037:antagonists & inhibitors; D013329:Structure-Activity Relationship
D016376:Oligonucleotides, Antisense; D010429:Pentoses; D012333:RNA, Messenger; D016914:Ribonuclease H